Latest Loan Repayment News

Papyrus Australia has taken a significant step towards commercialisation by signing a $4.2 million supply contract with TBS Mining Solutions for its biodegradable Collar Keeper® products, while advancing its Adelaide R&D facility.

Globe Metals & Mining has issued over 56 million shares to Director Bo Tan, settling nearly all of an outstanding loan and achieving a fully debt-free status. This financial milestone positions the company strongly for advancing its Kanyika Niobium Project.

Sheffield Resources has negotiated a waiver and deferral on senior loan repayments for its Thunderbird Mineral Sands Mine, while ongoing discussions with lenders aim to restructure project finance amid uncertain shareholder funding.

Epsilon Healthcare Limited has unveiled a comprehensive pre-reinstatement disclosure, highlighting improved financial health and a strategic growth plan focused on operational stability and expansion.

Epsilon Healthcare reported a 19% revenue increase to $3.4 million for the half year ended June 2025, driven by new client wins and its pharmacy segment launch. However, net losses widened 44% to $2.07 million, reflecting administration and financing costs during its recovery phase.

Central Iron Ore Limited has announced a rights offering to raise up to $2.89 million, aiming to support its South Darlot joint venture, advance drilling at British King Mine, and repay a loan to majority shareholder Gullewa Limited.

AdAlta Limited has received a $0.78 million Research and Development Tax Incentive refund for FY2025, using part of it to repay a Radium Capital loan and strengthening its cash position as it nears a key licensing milestone.

Renergen Limited and ASP Isotopes Inc. have secured crucial regulatory approvals and agreed to extend the deadline for completing their Scheme of Arrangement to January 2026, signaling steady progress in their strategic partnership.

Keybridge Capital Limited is navigating a complex recovery with new board leadership, partial loan repayments, and favorable court rulings against former executives. The company is steadily addressing legacy financial and legal challenges.

Audeara Limited has secured a $1.22 million R&D tax incentive refund for FY25, strengthening its financial position by repaying debt and retaining non-dilutive funding to fuel ongoing product development.

Zelira Therapeutics has received a $1.07 million cash refund under Australia’s R&D Tax Incentive Scheme, reinforcing its funding for ongoing clinical trials and product development. The company has also repaid a prior loan advanced against this claim, positioning it for continued growth in cannabinoid-based medicines.

ClearVue Technologies has secured an A$881k Australian Government R&D rebate and used part of it to retire a A$409k loan, strengthening its financial position as it advances its solar glass technology.